Screener
Halozyme Therapeutics HALO Prepaid & Other Current
Prepaid & Other Current at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PrepaidExpenseAndOtherAssetsCurrent.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
FAQ
- What is Halozyme Therapeutics's prepaid & other current?
- Halozyme Therapeutics (HALO) reported prepaid & other current of $109.06M in Q2 2026.
- How has Halozyme Therapeutics's prepaid & other current changed year-over-year?
- Halozyme Therapeutics's prepaid & other current increased by 42.3% year-over-year, from $76.65M to $109.06M.
- What is the long-term trend for Halozyme Therapeutics's prepaid & other current?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's prepaid & other current has grown at a 18.0% compound annual growth rate (CAGR), from $28.27M to $64.64M.
- What does prepaid & other current mean?
- Advance payments for expenses (rent, insurance, subscriptions) plus miscellaneous current assets not classified elsewhere.
Ask your AI about Halozyme Therapeutics's prepaid & other current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude